http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Performance of prototype neutron detectors for Large Acceptance Multi-Purpose Spectrometer at RAON
Shim, Hyunha,Lee, Jong-Won,Hong, Byungsik,Ahn, Jung Keun,Bak, Gyeonghwan,Jo, Jamin,Kim, Minho,Kim, Young Jin,Kim, Young Jun,Lee, Hanseul,Lee, Hyo Sang,Lee, Kyong Sei,Mulilo, Benard,Moon, Dong Ho,Ryu, Elsevier 2019 Nuclear Instruments & Methods in Physics Research. Vol.927 No.-
<P><B>Abstract</B></P> <P>The performance of the prototype modules of neutron detectors for the Large Acceptance Multi-Purpose Spectrometer (LAMPS) was investigated, using cosmic muons and neutron beams at 65 and 392 MeV, provided by the Research Center for Nuclear Physics (RCNP). The timing and position resolutions were estimated using cosmic muons as 309 ps and 4.8 cm, respectively. The energy resolution depended on the incident energy of neutrons: 1.3% at 65 MeV and 3.1% at 392 MeV. The neutron-detection efficiency also showed weak energy dependence as it decreased from (9.0 ± 1.6)% at 65 MeV to (6.3 ± 1.0)% at 392 MeV.</P>
Jung, Yeon Suk,Park, Jung Hwa,Kim, Hyunha,Kim, So Young,Hwang, Ji Young,Hong, Ki Whan,Bae, Sun Sik,Choi, Byung Tae,Lee, Sae-Won,Shin, Hwa Kyoung Springer Science and Business Media LLC 2016 Acta pharmacologica Sinica. Vol.37 No.8
<P>Aim: Increasing evidence suggests that probucol, a lipid-lowering agent with anti-oxidant activities, may be useful for the treatment of ischemic stroke with hyperlipidemia via reduction in cholesterol and neuroinflammation. In this study we examined whether probucol could protect against brain ischemic injury via anti-neuroinflammatory action in normal and hyperlipidemic mice. Methods: Primary mouse microglia and murine BV2 microglia were exposed to lipopolysaccharide (LPS) for 3 h, and the release NO, PGE2, IL-1 beta and IL-6, as well as the changes in NF-kappa B, MAPK and AP-1 signaling pathways were assessed. ApoE KO mice were fed a high-fat diet containing 0.004%, 0.02%, 0.1% (wt/wt) probucol for 10 weeks, whereas normal C57BL/6J mice received probucol (3, 10, 30 mg.kg(-1).d(-1), po) for 4 d. Then all the mice were subjected to focal cerebral ischemia through middle cerebral artery occlusion (MCAO). The neurological deficits were scored 24 h after the surgery, and then brains were removed for measuring the cerebral infarct size and the production of pro-inflammatory mediators. Results: In LPS-treated BV2 cells and primary microglial cells, pretreatment with probucol (1, 5, 10 mu mol/L) dose-dependently inhibited the release of NO, PGE2, IL-1 beta and IL-6, which occurred at the transcription levels. Furthermore, the inhibitory actions of probucol were associated with the downregulation of the NF-kappa B, MAPK and AP-1 signaling pathways. In the normal mice with MCAO, pre-administration of probucol dose-dependently decreased the infarct volume and improved neurological function. These effects were accompanied by the decreased production of pro-inflammatory mediators (iNOS, COX-2, IL-1, IL-6). In ApoE KO mice fed a high-fat diet, pre-administration of 0.1% probucol significantly reduced the infarct volume, improved the neurological deficits following MCAO, and decreased the total-and LDL-cholesterol levels. Conclusion: Probucol inhibits LPS-induced microglia activation and ameliorates cerebral ischemic injury in normal and hyperlipidemic mice via its anti-neuroinflammatory actions, suggesting that probucol has potential for the treatment of patients with or at risk for ischemic stroke and hyperlipidemia.</P>